Ciclosporin A topical - BioNanoSim/Immune Pharmaceuticals

Drug Profile

Ciclosporin A topical - BioNanoSim/Immune Pharmaceuticals

Alternative Names: CsA - Immune Pharmaceuticals; Cyclosporine-A - Immune Pharmaceuticals; Nano-cyclosporine A - Immune Pharmaceuticals; Nano-formulated cyclosporine A - Immune Pharmaceuticals; Nanocyclo

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Hebrew University of Jerusalem; Immune Pharmaceuticals Inc
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atopic dermatitis; Psoriasis

Most Recent Events

  • 16 Aug 2016 Immune Pharmaceuticals plans to file an IND application for Atopic dermatitis and Psoriasis in 2017
  • 16 May 2016 Immune Pharmaceuticals plans a phase II trial for Atopic dermatitis and Psoriasis in
  • 04 Jan 2016 Nano-ciclosporin A licensed to Immune Pharmaceuticals worldwide for the treatment of Atopic dermatitis and Psoriasis (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top